Notice: This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends FSDC vs. XENE, MLTX, MOR, MRUS, ZLAB, FOLD, BHC, CPRX, GMTX, and HCMShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Merus (MRUS), Zai Lab (ZLAB), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), and HUTCHMED (HCM). These companies are all part of the "medical" sector. FS Development vs. Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys Merus Zai Lab Amicus Therapeutics Bausch Health Companies Catalyst Pharmaceuticals Gemini Therapeutics HUTCHMED Xenon Pharmaceuticals (NASDAQ:XENE) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings. Does the media refer more to XENE or FSDC? In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than FS Development. MarketBeat recorded 5 mentions for Xenon Pharmaceuticals and 0 mentions for FS Development. Xenon Pharmaceuticals' average media sentiment score of 1.21 beat FS Development's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Xenon Pharmaceuticals Positive FS Development Neutral Do analysts recommend XENE or FSDC? Xenon Pharmaceuticals currently has a consensus target price of $56.00, indicating a potential upside of 43.66%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, XENE or FSDC? FS Development has lower revenue, but higher earnings than Xenon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M315.15-$182.39M-$2.82-13.82FS DevelopmentN/AN/AN/AN/AN/A Is XENE or FSDC more profitable? FS Development's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% FS Development N/A N/A N/A Do insiders and institutionals hold more shares of XENE or FSDC? 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 89.8% of FS Development shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer XENE or FSDC? Xenon Pharmaceuticals received 419 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes41969.95% Underperform Votes18030.05% FS DevelopmentN/AN/A SummaryXenon Pharmaceuticals beats FS Development on 10 of the 12 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$757.47M$6.54B$5.37B$9.12BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A5.6666.7714.56Price / SalesN/A357.981,264.1585.80Price / CashN/A22.3236.0932.90Price / BookN/A5.074.964.69Net IncomeN/A$154.90M$117.89M$224.57M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$60.52+3.9%N/A-10.0%$757.47MN/A0.00N/AXENEXenon Pharmaceuticals2.7646 of 5 stars$38.25-0.4%$56.00+46.4%-10.9%$2.92B$9.43M-13.56210Positive NewsMLTXMoonLake Immunotherapeutics1.9114 of 5 stars$45.26-2.3%$81.43+79.9%-14.4%$2.89BN/A-35.092MORMorphoSys0.212 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730MRUSMerus3.3727 of 5 stars$40.45-7.8%$85.64+111.7%+13.6%$2.77B$35.93M-10.2437Positive NewsHigh Trading VolumeZLABZai Lab2.4982 of 5 stars$25.21-0.4%$55.00+118.2%+10.9%$2.76B$355.75M-9.102,175Analyst RevisionFOLDAmicus Therapeutics4.4226 of 5 stars$9.23+2.3%$16.88+82.8%-20.9%$2.76B$493.67M-27.15480Analyst RevisionBHCBausch Health Companies3.3021 of 5 stars$7.40-6.1%$7.75+4.7%-8.3%$2.68B$9.47B-15.4220,270Analyst RevisionPositive NewsHigh Trading VolumeCPRXCatalyst Pharmaceuticals4.7933 of 5 stars$22.21+1.3%$32.86+47.9%+57.4%$2.65B$460.48M18.8280News CoverageGMTXGemini TherapeuticsN/A$59.25-5.3%N/A-10.0%$2.57BN/A-59.2530High Trading VolumeHCMHUTCHMED2.3758 of 5 stars$14.51-3.5%$19.00+30.9%-0.4%$2.53B$420.26M0.001,988Positive NewsGap Down Related Companies and Tools Related Companies Xenon Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors MorphoSys Competitors Merus Competitors Zai Lab Competitors Amicus Therapeutics Competitors Bausch Health Companies Competitors Catalyst Pharmaceuticals Competitors Gemini Therapeutics Competitors HUTCHMED Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FSDC) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FSDC Stock Alerts